Wikidata entity: Q413772
C₁₀H₁₂N₂ (P274)
Quantities
| P4250 | defined daily dose | 75 |
| P2067 | mass | 160.1 |
| P233 | canonical SMILES | String | C1CN=C(N1)CC2=CC=CC=C2 | ??? |
| P373 | Commons category | String | Tolazoline | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2175 | medical condition treated | ... | Q746001 (thromboangiitis obliterans) | thromboangiitis obliterans |
| P2175 | medical condition treated | ... | Q1053824 (Raynaud disease) | Raynaud disease |
| P2175 | medical condition treated | ... | Q377978 (thrombophlebitis) | thrombophlebitis |
| P2175 | medical condition treated | ... | Q18555343 (causalgia) | causalgia |
| P2175 | medical condition treated | ... | Q4797546 (arteriosclerosis obliterans) | arteriosclerosis obliterans |
| P2175 | medical condition treated | ... | Q5340515 (systemic scleroderma) | systemic scleroderma |
| P2175 | medical condition treated | ... | Q7170410 (persistent fetal circulation syndrome) | persistent fetal circulation syndrome |
| P129 | physically interacts with | ... | Q21141045 (Adrenoceptor alpha 2B) | Adrenoceptor alpha 2B |
| P129 | physically interacts with | ... | Q4734891 (Adrenoceptor alpha 2C) | Adrenoceptor alpha 2C |
| P129 | physically interacts with | ... | Q4734892 (Adrenoceptor alpha 2A) | Adrenoceptor alpha 2A |
| P279 | subclass of | ... | Q11173 (chemical compound) | chemical compound |
| P2868 | subject has role | ... | Q1927838 (alpha blocker) | alpha blocker |
| P2868 | subject has role | ... | Q575890 (antihypertensive drug) | antihypertensive drug |
| P2868 | subject has role | ... | Q4008956 (vasodilator agent) | vasodilator agent |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | tolazoline | ??? |
Why not click here or view trends?
log id: 3020814